Showing results (611-620 of 2,688) with videos related to

Sort By:
Pageof 269
The Lancet. Infectious Diseases|March 14, 2024
Accelerating antibiotic access and stewardship: a new model to safeguard public healthJennifer Cohn, Marc Mendelson, Souha S Kanj, et al.
The Lancet. Infectious Diseases|March 9, 2024
Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trialChijioke Bennett, Wayne Woo, Mark Bloch, et al.
The Lancet. Infectious Diseases|February 17, 2024
Managing treatment failure in Neisseria gonorrhoeae infection: current guidelines and future directionsLao-Tzu Allan-Blitz, Helen Fifer, Jeffrey D Klausner
The Lancet. Infectious Diseases|February 29, 2024
Effect of BCG vaccination against Mycobacterium tuberculosis infection in adult Brazilian health-care workers: a nested clinical trialPaulo Cesar Pereira Dos Santos, Nicole Louise Messina, Roberto Dias de Oliveira, et al.
The Lancet. Infectious Diseases|April 12, 2024
Listeria monocytogenes-associated spontaneous bacterial peritonitis in France: a nationwide observational study of 208 casesFlorian Blanchard, Benoît Henry, Sofieya Vijayaratnam, et al.
The Lancet. Infectious Diseases|April 6, 2024
Viral shedding and viraemia of Andes virus during acute hantavirus infection: a prospective studyMarcela Ferrés, Constanza Martínez-Valdebenito, Carolina Henriquez, et al.
The Lancet. Infectious Diseases|February 18, 2024
Transjugular intrahepatic portosystemic shunt followed by splenectomy for complicated hepatosplenic schistosomiasis: a case report and review of the literatureFrancesca Tamarozzi, Tamara Ursini, Giacomo Stroffolini, et al.
The Lancet. Infectious Diseases|February 4, 2024
Mucormycosis after CD19 chimeric antigen receptor T-cell therapy: results of a US Food and Drug Administration adverse events reporting system analysis and a review of the literatureKathleen P L Cheok, Adrian Farrow, Deborah Springell, et al.
The Lancet. Infectious Diseases|May 20, 2024
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trialMuge Cevik, Lindsay C Thompson, Caryn Upton, et al.
The Lancet. Infectious Diseases|April 27, 2024
Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV)Phrutsamon Wongnak, William H K Schilling, Podjanee Jittamala, et al.
Pageof 269